Thanks Mike.
from we programs, quarter, the believe topline third serve summarize depth the drivers a development as we our to agonist. I'll announcements results the highlights now. value pleased beta VKXXXX, pipeline. II were multiple the XX-week in highlighting our of of which thyroid of reminder Phase our study During an In announce receptor September, data novel we important breadth and made positive from
As the a well hormone or available as an reminder, receptor for lipid thyroid steatohepatitis subtype, suggesting range selectivity beta disorders, as agonists of liver therapeutic the in tissue, that receptor orally of including is VKXXXX non-alcoholic a possesses NASH. promising potential
study VKXXXX parallel receive randomized and trial's non-alcoholic primary endpoint Our every or and placebo XX a of the for The fatty safety, weeks everyday Phase LDL-cholesterol group double-blind, doses efficacy, oral with milligram day effect II placebo. other disease trial XX the to evaluate weeks. placebo of randomized, in to Patients was tolerability patients VKXXXX to XX VKXXXX or were VKXXXX evaluated liver compared on controlled milligrams LDL-cholesterol. elevated of designed XX of after
September experienced placebo-treated LDL-C that successfully fraction in secondary the patient. the MRI fat The trials endpoint. which study endpoint, and many Other fat changes and proton We the XX VKXXXX interest were greatest report demonstrated reductions achieved safety compared endpoints the patients significant for secondary primary its primary density receiving with pleased in change tolerability. liver the lipid, in assess assess With that by results weeks. was statistically endpoint the after to in endpoint, respect of atherogenic to
improvements lipoprotein A. VKXXXX-treated addition, including statistically and in atherogenic significant B experienced other lipids, patients apolipoprotein In the proteins,
important our endpoint secondary are the endpoint, path results are primary more future happy for for achieve to we for even While potentially our development VKXXXX.
reported As VKXXXX unprecedented liver in results content other demonstrated topline oral experienced that in compared receiving we September, reductions patients with fat agents.
experienced as a relative is weeks NASH receiving conducted. patients milligrams liver approximately median of receiving content is of other X%. milligrams these XX% magnitude these The of experienced encouraging. dosed of very from today, median relative head-to-head interest as fat odds XX% as knowledge, low a our in threshold they percent comparison, than studies this histology in by VKXXXX these By fat been differentiated XX particularly doses characterized assessed relative agents receiving day if Trial provide for is in reduction so liver of view XX responders NASH. every at efficacy analysis, corresponding from included fat increase for that have liver no Patients benefit. important by approximately liver observed. the or We development baseline. of was Specifically placebo fat XX% clinical reduction liver predict is to median liver baseline intended fat of fat measure responder VKXXXX were daily studies To relatively of content XX% experienced may the liver doses experienced MRI-PDFF. XX believe for unprecedented features that also targeting among liver have is the more, VKXXXX one had a relative this results at reduction content. effects, reduction overall in on demonstrated which patients equal doses a at these oral the reduction approximately and magnitude in modest fat observed improved to broader whether unique reduction benefit reduced our multiple also greater support This or assess Patients
patients analysis treated XX% other liver approximately VKXXXX dosed revealed among encouraging Among dose fat. demonstrated in a at XX Our milligrams with content. data approximately fat of treated XX% least VKXXXX day, results, XX% at XX per with responder liver demonstrated patients in reduction every our at of XX%, a milligrams day, reduction least
we overall the experienced term VKXXXX or or received reduction and intriguing the was in reduced reported patients an serious study. outcome than substantially approximately course In safety, for depth, breadth over study. XX% XX% was liver analysis coined shown or VKXXXX compelling in responder numbers observed but shown it liver adverse who histology fat events relatively the at evenly No well across arms. define is to the We Starting at not of safe VKXXXX be two-thirds also this were signal reduction as and fat. this XX% among also which The this This to larger population adverse the were responder the super or to this a of only found exercise in to all study of confirms distributed patients receiving placebo. looking improve. XX% performed events We because in greater this additional study. believe been whose half is treatment relative analysis, of patients by tolerated XX% the has
slightly there to among were placebo. patients numerically, So observed randomized more
safety to the tolerability We're by well thus Overall, therapeutic of the results VKXXXX tolerated point measures. Finally, far, believe in it shown extremely was study. profile efficacy effects display VKXXXX. these be particularly demonstrated profile, pharmacodynamic best-in-class the and potent this we a in in encouraged light to for
abstract which our which we October, of the is receipt presentation the the for a Study Association I, acceptance abstracts part late-breaker Session Meeting be San Diseases. American Monday, say at of Annual we're happy the in In will we of of Following place will to on notified take the for the submitted XX presentation are Francisco. Liver Liver and Oral results, Late-Breaking November our meeting, that of Abstract
AASLD, our each were for abstract nominated particular In the addition, of important we meeting. in inclusion best serves to that which highlight been at contributions informed of has annual
with are and XXXX. VKXXXX, focus preparing with next these a will this advisors study the file diligently NASH. Given intense next we're working with IND which in to topic forward. initiate design process in at steps an At study path the we in we for patients a biopsy-confirmed we anticipate on results, is The point, of clinical best of the study company of that plan and the clinical involve our
our we and with had for of glycogen NASH, in in proceed the efforts implementation we area disease. the evaluating As next planning also of been steps storage VKXXXX
as a and updates, has fat GSD in produce of the VKXXXX VKXXXX reductions as inflammation vivo NASH. Ia GSD demonstrated characteristics content In compounds in in in benefit impressive potential that efficacy models on both discussed substantial improvements As liver in work, and autophagy, well are which this we've prior as reminder, Ia. support
II in Phase NASH. given the efforts we focus to decided our have study, was development VKXXXX more signal closely observed of efficacy However, that the our for on recent
an possesses commonly a in beta important long thyroid plasma to to we observed reflects not a is very to for I in the orally of a that enthusiasm cerebral dedicate and plan a These I'd program, often toxicities thyroid fatty the for lack markers this in and available program potential VKXXXX the XX-week and receptor X-linked to motor update evaluating chain GSP turn tissue. to study subtype in disease IND small our program this Sustained molecule pharmacologic Institute to potential receptor selectivity in as setting. potential in receptor result, notably will NASH our Ia. attention X-ALD. Krieger enabling the VKXXXX elevations patients therefore The providing collaborators acids model the We're and a selective defect this the It this year, our successfully study orphan XXXX. conducting to the X-ALD for is to agonist disease androgen us required receptor to that tissue. disease. result execute chain at work we long the is concept fatty now by of benefit an ABCD-X. caused metabolism small VKXXXX this modulator imply in transporter IND in to treatment beta Activation a for program time VKXXXX, does effectively of As want provide fatty on other in accumulation like in may evaluating and plan by required GSD in currently agonists long Ia. to animal plasma in stimulate allow clinical disorders. X-ALD. on very very at merely emphasize clinical to disease, now of the acids, the contribute manage for receptor focus chain benefit. acid musculoskeletal are approach molecule acids to chain effects or study I’ll levels not neuron any fatty a characterized a and showed improvement our Viking’s VKXXXX a severe promising of an peroxisomal disease. file work novel devastating additional defer represent conduct Last both a belief potential thyroid Kennedy proof an of which believed completed long adrenoleukodystrophy called is an very therapeutic in believed of are
As skin reduced to as bone with activity and such a reminder, in VKXXXX is selectively prostate. peripheral designed tissues formation stimulate and muscle
loss of further accelerated hip of to prolonged muscle morbidity, a and them refracture many and fracture, bone Following surgery repair placing patients experience rates at increased risk at disability.
The option fracture reasons, hip of formation and and Phase an bone from as these incidence health of muscle results achieved head, lean a stimulating its hip fracture belief patients our improving we hip these recovering the successfully may for VKXXXX showed represent following Topline treatment important demonstrating statistically last from and endpoint the The from significant were VKXXXX fracture For condition recovery our trial II announced increases November primary other in year. by in dose-dependent in with continue of less thereby and body with placebo. mass, lean increase. endpoints as well is the facilitating the in-patients as medical total continues age as to compared population all mass statistically to serious data treatment injury. musculoskeletal increases study doses achieved VKXXXX that also important placebo. will to for is significant demonstrating mass, body our compared injuries of lean secondary It study appendicular believe
treatment numerical arms. functions favoring trends In though significance, powered showed endpoints addition, physical assessing not for also
also this reported. with Importantly drug-related in no events demonstrated VKXXXX tolerability study encouraging serious adverse safety and
was third part meeting oral for Phase of the notified our the were selected mineral bone quarter and American annual the presentation that the results for Viking as During Society II of from research. session plenary the study at
honored in at quality results this we treatment to position addition, data of were organizers. Outstanding study by recognition We been needed to prominent as well our that speaks we as such a this Conference the and that have much potential generated a The the Award September offer VKXXXX meeting. for the this abstract important the were In setting. believe Abstract on option about informed XX Most presented awarded had were received the Clinical ASBMR
C fracture. Type Later discuss to hip useful regulatory further to meeting answers potential second to request quarter, our VKXXXX hip the in third the meeting quarter of for VKXXXX development we received briefing the posed the FDA comments questions provide forward fracture. the in path for Type input During These package. submitted we C written in for
in in franchise. our calls, on best particularly would indication be any of with partner, existing indicated studies one an musculoskeletal we've by bone subsequent As prior executed orthopedic or view, VKXXXX
VKXXXX optimize allow value move efficient to We opportunities the the continue most manner of the us explore forward program possible. in will partnering that to and
comments as provide up corporate activities on with will updates recent warranted. some We these on wrap now activity. a I'll
financial announcement our stock and data a quarter that pipeline completed provides Phase expect the positive the common beyond This VKXXXX, financing During offering which it approximately runway will aggressively resulted a following II funds of gross we third XXXX. million. with to we advance of of proceeds us provides for successful extend in needed programs the $XXX
NASH. participated liver we this of just VKXXXX during the outstanding conclusion, the that honored to organizers. data grateful Also most their presenting fatty indicating for the in all the as diseases Annual announced continued investors we a in by our wish are have for recognized forward. during Meeting to thank therapeutic We presented VKXXXX investors look potential at and the data such to Phase forward days. We promise offering In quarter, II ASBMR as quarter, program from we third who as to the holds abstract move these results our and tremendous II conference Phase the we’re a clinical as few support
Operator? potential again our in investors for And Viking us. the team success an I'd like VKXXXX. from for advancing We Thanks clinical for exceptional X-ALD. continuing explore and our pipeline VKXXXX a program statements to our for planned clinic questions. positioned proof-of-concept we the in with trial XXXX. now finally, today. partnering assets combined our to by this program with build joining IND concludes partners. continue currently We to for call have and for our to And prepared and the further support file for These initiate open are This opportunities
